Matrine sustained releasing agent and its preparing process

Abstract

A slowly releasing kurarinol in the form of tablet is prepared from kurarinol, diluent, adhesive and lubricant through pulverizing, proportional mixing, adding alcohol to prepare soft material, sieving by 20 meshes, drying at 50+ / -5 deg.C, sieving by 18 meshes, mixing with lubricant, and tabletting. Its advantages are balanced concentration in blood, durable action and low by-effect.

Description

technical field [0001] The invention relates to a new pharmaceutical dosage form of matrine, in particular to a slow-release agent of matrine and a preparation process thereof. Background technique [0002] Kushensu is an active ingredient extracted from the traditional Chinese medicine Sophora alopecuroides L or Sophoraflavescens Ait, which contains more than 98% of oxymatrine. Pharmacological and clinical studies have shown that Kushen Ginseng has the functions of anti-tumor, antibacterial, anti-virus, improving liver function, preventing liver fibrosis, reducing transaminase, and improving immunity of the body. After taking matrine, the replication level of hepatitis B virus in the infected cells in the body decreased significantly Quantitative detection of genes), alanine aminotransferase and bilirubin in patients with chronic hepatitis B recovered to normal rate reached 81.6% and 69.9% respectively. Therefore, matrine has been identified as a key promotional engineerin...

AI Technical Summary

Problems solved by technology

[0003] At present, matrine preparations on the market mainly include injections, infusions, quick-release capsules and tablets. However, due to the excellent water solubility of matrine, it is not easy to control the release rate. Inside, the blood drug concentration is very low, and then released quickly, so that the blood drug concentration in the body suddenly rises, and an obvious peak appears, as shown in Table 1, thereby enhancing the toxic and side effects of the drug

At the same time, from the perspective of therapeutic compliance, patients often forget to take medicines during the day when ordinary preparations are taken three times a day, and taking medicines three times a day should be administered once every minute or hour in theory, but in practice it is very difficult. The time interval between the three times is short, and the time from taking the medicine at night to the morning is long, resulting in low blood drug concentration in the morning and early morning, and the drug's efficacy is not stable.

Therefore, the use of existing dosage forms is far from being suitable for clinical needs, and the development of sustained-release preparations once or twice a day is adapted to the needs of the current medical market.

Images